1-5 of 5
Susan Jones-Bolin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract #3736: In vitro activity and in vivo efficacy of a benzazepinone ALK inhibitor on human neuroblastoma-derived cell lines

Lihui Lu, Mattew quail, Melissa Jones, Monalisa ghose, Ann DeVine, Gregory gregory, Susan Jones-bolin, Bruce dorsey, Bruce ruggeri, Mangeng Cheng
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3736.
Published: 01 May 2009
View article titled, Abstract #3736: <em>In vitro</em> activity <em>and in vivo</em> efficacy of a benzazepinone ALK inhibitor on human neuroblastoma-derived cell lines
Journal Articles

Anti-tumor effects of fatty acid synthase inhibitor C75 on orthotopically-implanted human pancreatic ductal adenocarcinoma in nude mice.

Hui Qin Wang, Bruce A. Ruggeri, Deborah A. Altomare, Susan Jones-Bolin, Hugh Zhou, Joseph R. Testa
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 699.
Published: 01 April 2004
View article titled, Anti-tumor effects of fatty acid synthase inhibitor C75 on orthotopically-implanted human pancreatic ductal adenocarcinoma in nude mice.
Journal Articles

Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist

Pawel Dobrzanski, Kathryn Hunter, Susan Jones-Bolin, Hong Chang, Candy Robinson, Sonya Pritchard, Hugh Zhao, Bruce Ruggeri
Journal: Cancer Research
Cancer Res (2004) 64 (3): 910–919.
https://doi.org/10.1158/0008-5472.CAN-3430-2
Published: 10 February 2004
View article titled, Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist
Open the PDF for Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist in another window
Journal Articles

CEP-7055: A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models

Bruce Ruggeri, Jasbir Singh, Diane Gingrich, Thelma Angeles, Mark Albom, Hong Chang, Candy Robinson, Kathryn Hunter, Pawel Dobrzanski, Susan Jones-Bolin, Lisa Aimone, Andres Klein-Szanto, Jean-Marc Herbert, Francoise Bono, Paul Schaeffer, Pierre Casellas, Bernard Bourie, Roberto Pili, John Isaacs, Mark Ator, Robert Hudkins, Jeffry Vaught, John Mallamo, Craig Dionne
Journal: Cancer Research
Cancer Res (2003) 63 (18): 5978–5991.
Published: 01 October 2003
View article titled, CEP-7055: <subtitle>A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models</subtitle>
Open the PDF for CEP-7055: <subtitle>A Novel, Orally Active Pan Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models</subtitle> in another window
Journal Articles

CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth

Christopher J. Strock, Jong-In Park, Mark Rosen, Craig Dionne, Bruce Ruggeri, Susan Jones-Bolin, Samuel R. Denmeade, Douglas W. Ball, Barry D. Nelkin
Journal: Cancer Research
Cancer Res (2003) 63 (17): 5559–5563.
Published: 18 September 2003
View article titled, CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth
Open the PDF for CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth in another window